{"organizations": [], "uuid": "6444f9226f5baf7eb05aa87d56d848d956186a60", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-syros-pharmaceuticals-reports-q4-l/brief-syros-pharmaceuticals-reports-q4-loss-per-share-0-58-idUSASC09RQI", "country": "US", "domain_rank": 408, "title": "BRIEF-Syros Pharmaceuticals Reports Q4 Loss Per Share $0.58", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-12T13:26:00.000+02:00", "replies_count": 0, "uuid": "6444f9226f5baf7eb05aa87d56d848d956186a60"}, "author": "", "url": "https://www.reuters.com/article/brief-syros-pharmaceuticals-reports-q4-l/brief-syros-pharmaceuticals-reports-q4-loss-per-share-0-58-idUSASC09RQI", "ord_in_thread": 0, "title": "BRIEF-Syros Pharmaceuticals Reports Q4 Loss Per Share $0.58", "locations": [], "entities": {"persons": [{"name": "joseph j. ferra", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "syros pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 12, 2018 / 11:26 AM / in 8 minutes BRIEF-Syros Pharmaceuticals Reports Q4 Loss Per Share $0.58 Reuters Staff 1 Min Read March 12 (Reuters) - Syros Pharmaceuticals Inc: * SYROS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT ACCOMPLISHMENTS AND ANTICIPATED MILESTONES * Q4 LOSS PER SHARE $0.58 * Q4 EARNINGS PER SHARE VIEW $-0.57 â€” THOMSON REUTERS I/B/E/S * ANNOUNCED APPOINTMENT OF JOSEPH J. FERRA AS CHIEF FINANCIAL OFFICER * SYROS PHARMA - BELIEVES CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 WILL BE SUFFICIENT TO ENABLE CO TO FUND PLANNED OPERATING EXPENSE, CAPEX INTO 2020 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-12T13:26:00.000+02:00", "crawled": "2018-03-12T13:40:28.024+02:00", "highlightTitle": ""}